Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Department of Nursing, Taipei Veterans General Hospital, Taipei, Taiwan.
J Gastrointest Surg. 2024 Aug;28(8):1250-1258. doi: 10.1016/j.gassur.2024.05.020. Epub 2024 May 21.
The clinical outcomes between left-sided colon cancer and middle/low rectal cancer seem to be different. This study aimed to examine the effect of primary tumor location regarding the left-sided colon and middle/low rectum on the overall survival (OS) of patients who underwent colorectal hepatic metastasectomy.
Patients who underwent colorectal hepatic metastasectomy were retrospectively enrolled. Patients were classified into 2 groups according to the primary tumor location (left-sided colon and middle/low rectum). Categorical variables were compared using the chi-square test or Fisher exact test, and continuous variables were analyzed using the Student t test. Survival was analyzed using the Kaplan-Meier method and log-rank test. The prognostic factors were analyzed by univariate and multivariate analyses using Cox proportional hazards regression models.
Overall, 365 patients were enrolled. Patients with left-sided colon cancer had significantly better OS than those with middle/low rectal cancer (hazard ratio [HR], 0.725; P = .018), with median OS estimates of 48 and 38 months, respectively. In the subgroup analysis of RAS mutations, patients with left-sided colon cancer had significantly prolonged OS compared with those with middle/low rectum cancer (HR, 0.608; P = .034), with median OS estimates of 49 and 26 months, respectively. This observation was limited to patients with RAS mutations.
According to our findings, patients with middle/low rectal cancer had poorer survival outcome and should not be categorized together with patients with left-sided colon cancer in terms of OS after colorectal hepatic metastasectomy.
左半结肠癌和中低位直肠癌的临床结局似乎不同。本研究旨在探讨原发肿瘤位于左半结肠和中低位直肠对接受结直肠肝转移瘤切除术患者总生存(OS)的影响。
回顾性纳入接受结直肠肝转移瘤切除术的患者。根据原发肿瘤位置(左半结肠和中低位直肠)将患者分为 2 组。使用卡方检验或 Fisher 确切检验比较分类变量,使用学生 t 检验分析连续变量。使用 Kaplan-Meier 方法和对数秩检验分析生存情况。使用单因素和多因素 Cox 比例风险回归模型分析预后因素。
共纳入 365 例患者。左半结肠癌患者的 OS 明显优于中低位直肠癌患者(风险比 [HR],0.725;P =.018),中位 OS 估计值分别为 48 个月和 38 个月。在 RAS 突变的亚组分析中,左半结肠癌患者的 OS 明显长于中低位直肠癌患者(HR,0.608;P =.034),中位 OS 估计值分别为 49 个月和 26 个月。这种观察仅限于 RAS 突变患者。
根据我们的发现,中低位直肠癌患者的生存结局较差,在接受结直肠肝转移瘤切除术的 OS 方面不应与左半结肠癌患者归为一类。